Preview Mode Links will not work in preview mode

PODCAST SBD - PROFISSIONAL

Sep 30, 2020

Autor: Antônio Carlos Pires

Ref: The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care. 2016 Feb;39(2):198-205

 


Sep 30, 2020

Autor: Alexander Benchimol

Ref: Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34


Sep 30, 2020

Autor: Fernando Valente

Ref: Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? No, We Should Never Again Compromise Safety! Diabetes Care. 2016 Jul;39(7):1281-6.

e

Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss? 


Sep 25, 2020

Autora: Fani Eta Korn Malerbi

Ref: HypoAware: development and pilot study of a brief and partly web-based psychoeducational group intervention for adults with Type 1 and insulin-treated Type 2 diabetes and problematic hypoglycaemia. Diabet Med. 2016 Feb;33(2):184-91


Sep 25, 2020

Autor: Roberto Luís Zagury

Ref: Branched-chain amino acids in metabolic signaling and insulin resistance. Nat Rev Endocrinol. 2014 Dec;10(12):723-36